- Open Access
Erratum to: Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer
Journal of Experimental & Clinical Cancer Researchvolume 35, Article number: 95 (2016)
The original article was published in Journal of Experimental & Clinical Cancer Research 2016 35:70
Unfortunately, the original version of this article  contained an error. The name of one of the authors, Sharad Sharma, was not included in the author list.
The correct author list and the new “Authors’ contributions” section have been correctly included in full in this erratum and updated in the original article.
Feng L, Yao HP, Sharma S, Zhou YQ, Zhou J, Zhang R, et al. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. J Exp Clin Cancer Res. 2016;35(1):70. doi:10.1186/s13046-016-0347-6.
LF and HPY contribute equally to this work. LF was involved in preparation of antibody-drug conjugation, some in vitro and in vivo studies related to NSCLC. SS was involved in antibody characterization, some in vitro studies related to breast cancer. HPY and YQZ produced and purified anti-RON antibody, participated in some in vitro experiment, analyzed data, and provided partial funds for this project. JWZ provided experimental design and technical support for some intro experiments. RWZ participated in experimental design for combination study. MHW designed the study, participated in data analysis, wrote the manuscript, and secured the fund for completion of this study. All authors read and approved the final manuscript.
The online version of the original article can be found under doi:10.1186/s13046-016-0347-6.